Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
The U.S. Food and Drug Administration (FDA) has approved Phesgo, an under-the-skin injection of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, as a faster and more convenient alternative to treat people with ... Read more
After a recommendation from the U.S. Food and Drug Administration (FDA), CytoDyn is planning to ask the regulatory agency for a preliminary meeting to discuss the granting of breakthrough therapy ... Read more
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain ... Read more
The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this ... Read more
A new imaging agent that successfully measures changes in progesterone receptor (PR) levels may be used to determine if a breast cancer patient will respond to hormone therapies targeting ... Read more
One in three women with metastatic triple-negative breast cancer — all of whom had received at least two prior treatments — saw their tumors shrink after receiving Immunomedics‘ investigational treatment sacituzumab govitecan as ... Read more
A combination of MacroGenics‘ HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose ... Read more
Sermonix is launching a Phase 2 trial to determine if its lead investigational medicine lasofoxifene is better than Faslodex (fulvestrant) at delaying disease progression or death in breast cancer patients ... Read more
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Pfizer’s application for talazoparib, a candidate for the treatment of metastatic breast cancer in ... Read more
Parenting concerns are a major factor contributing to the psychological distress of women with late-stage cancer, and are associated with a lower quality of life, a study has found. ... Read more
Pin It on Pinterest